ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1342	National Cancer Institute	Html	en	Secondhand Smoke and Cancer	A fact sheet that summarizes the studies on the health effects of exposure to environmental (secondhand) tobacco smoke.	safe level 0.379875 passive smoke 0.502001 Human Services 0.468341 nonsmoking adults 0.357216 secondhand tobacco smoke 0.68104 U.S. Department 0.464191 lung cancer 0.378247 Cancer Progress Report 0.355171 burning tobacco product 0.42493 secondhand smoke 0.997055 Environmental Health Hazard 0.364487 Tobacco Control Monograph 0.372592 tobacco smoke 0.693112 U.S. Surgeon General 0.402428 Tobacco Smoke Causes 0.494425 tobacco products 0.362817 nationwide health promotion 0.362703 Environmental Tobacco Smoke—ETS 0.377837 Environmental Protection Agency 0.465583 contain harmful chemicals 0.358856 health effects 0.390654 disease prevention agenda 0.353662 United States 0.418836 National Toxicology Program 0.432935 health promotion 0.395997	U.S. Environmental Protection 0.431643 sudden infant death 0.405056 public places 0.357277 U.S. National Toxicology 0.366163 infant death syndrome 0.405701 heart disease 0.378172 smoking 0.358862 National Cancer Institute 0.4772 smoke cause cancer 0.529335 heart disease deaths 0.35595 Respiratory Health Effects 0.361324 tobacco product 0.437535 secondhand smoke exposure 0.747052 sinus cavity cancer 0.360979 health 0.407857 tobacco smoke cause 0.527224 environmental tobacco smoke 0.625449 Chronic Disease Prevention 0.389 lung cancer deaths 0.360096 Surgeon General 0.4042 Public Health Service 0.390186 involuntary smoke 0.507716 ear infections 0.356303 testing indoor air 0.35347	CLICK HERE
1344	National Cancer Institute	Html	en	How To Handle Withdrawal Symptoms and Triggers When You Decide To Quit Smoking	This fact sheet provides helpful tips related to smoking cessation.	routine smoke breaks 0.282965 smoking effects 0.278771 relaxation techniques 0.313407 nicotine addiction 0.355656 Control Research Branch 0.30123 Yes. Nicotine replacement 0.344131 nicotine withdrawal symptoms 0.36823 urge 0.354906 tips 0.337093 negative feelings 0.295635 Nicotine nasal spray 0.380205 tea 0.279209 Tobacco Control Research 0.298555 things 0.265705 tobacco smoke 0.262113 nicotine replacement therapy 0.347084 drinking coffee 0.292775 highly dependent smokers 0.261935 daily life 0.289451 Smoking Quitline 0.271985 Step-by-Step Quit Guide 0.333256 nicotine replacement products 0.922705 help quitting tobacco 0.287795 nicotine replacement product 0.346885 smoking increase 0.274802	weight gain 0.385772 smokers 0.365077 counter weight gain 0.289631 nicotine cravings 0.53551 nicotine doses 0.315612 common negative feelings 0.293918 smoking 0.59993 nicotine lozenge 0.318321 nicotine inhaler 0.328106 nicotine travels 0.313333 nicotine level drops 0.347286 chews nicotine gum 0.341989 people 0.407906 strong urge 0.298124 physical activity 0.320031 people smoking 0.295038 nicotine gum 0.386182 nicotine patch 0.339006 withdrawal symptoms 0.655994 common withdrawal symptoms 0.360181 coffee 0.312007 smoking cessation trials 0.292819 Occasional mild cravings 0.284899 time 0.303672	CLICK HERE
1805	National Cancer Institute	Html	es	Tratamiento del cáncer de ano (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del cáncer de ano.	Anal Cancer Trial 0.489207 results from 0.31371 John M 0.347549 with external radiotherapy 0.314904 anal canal 0.794085 combined modality therapy 0.350825 Trial Working Party 0.324488 randomized intergroup study 0.336989 Radiation Therapy Oncology 0.354467 perianal epidermoid cancers 0.314329 Radiat Oncol Biol 0.493627 anal intraepithelial neoplasia 0.3483 Natl Cancer Inst 0.358284 Flam M 0.355801 epidermoid carcinoma 0.391708 patients with 0.3347 radiation therapy 0.487367 preoperative multidisciplinary therapy 0.316168 squamous carcinoma 0.31988 intraepitelial anal ii–iii 0.32888 Krall JM 0.319145 Cancer Trial Working 0.342892 estadio ii 0.314589 Pajak TF 0.321788 Therapy Oncology Group 0.342392	with anal squamous 0.330697 anal carcinoma 0.555894 patients with carcinoma 0.314283 adjuvant combined modality 0.322897 combined with chemotherapy 0.336207 Oncology Group study 0.357157 Cancer Research 0.342768 therapy combined with 0.337029 Definitive irradiation 0.321135 randomised ukcccr anal 0.326366 interim report 0.31903 versus radiotherapy 0.314135 Clin Oncol 0.342577 Sischy B 0.347382 Oncol Biol Phys 0.504444 UK Co-ordinating Committee 0.321139 anal cancer 0.987825 definitive nonsurgical treatment 0.344247 optimal radiation 0.320998 advanced anal canal 0.329424 UKCCCR Anal Cancer 0.435954 implantation combined with 0.313892 anal canal carcinoma 0.398943 Doggett RL 0.318887	CLICK HERE
1864	National Cancer Institute	Html	es	Tratamiento de las neoplasias mieloproliferativas crónicas (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento de las neoplasias mieloproliferativas crónicas.	mutación jak2 0.0546285 Campbell PJ 0.0405614 primary myelofibrosis 0.131535 polycythaemia vera 0.093088 Health Organization classification 0.0291993 have myelofibrosis with 0.0314259 Mesa RA 0.119444 or calr mutation 0.036061 with nonmutated jak2 0.0536842 myeloproliferative neoplasms 0.261769 thousand patients with 0.0269901 with polycythemia vera 0.195275 Vera Study Group 0.0949279 leucemia mielógena 0.0351738 polycythemia vera with 0.109106 stem cell transplantation 0.0588703 transfusion-dependent patients with 0.0283801 patients with philadelphia 0.0316383 myeloproliferative disorders 0.146587 vera with jak2v617f 0.038469 calr mutation 0.0482163 Leuk Lymphoma 0.0369689 with essential thrombocythemia 0.0866875 patients with 0.725855 Verstovsek S 0.0388869	essential thrombocythemia 0.44083 patients with primary 0.0790517 metaplasia with myelofibrosis 0.0416952 with myeloid metaplasia 0.913374 essential thrombocythaemia 0.0355199 CALR mutation status 0.0373736 Organization classification system 0.0297845 with primary myelofibrosis 0.0630012 jak2 or calr 0.0410501 sudores nocturnos 0.0340921 leucemia aguda 0.0337979 patients with myelofibrosis 0.203296 vera with recombinant 0.0414353 Thiele J 0.0617064 patients with polycythemia 0.16042 myelofibrosis with 0.580226 polycythemia vera 0.713605 Tefferi A 0.30746 thrombocythemia with substantially 0.0550099 Polycythemia Vera Study 0.106061 with substantially different 0.0495287 Clin Oncol 0.190573 neoplasms with nonmutated 0.0489374 essential thrombocythemia with 0.102281	CLICK HERE
2029	National Cancer Institute	Html	es	Prevención del cáncer de seno (mama) (PDQ®)–Versión para profesionales de salud	Sumario de información revisada por expertos sobre factores que influyen en el riesgo de presentar cáncer de mama y sobre las investigaciones dirigidas a la prevención de esta enfermedad.	Sestak I 0.314213 Methods Mol Biol 0.309681 menor incidencia 0.315649 Breast Cancer Surveillance 0.32247 largo plazo 0.325123 Risk Calculator 0.330192 Cuzick J 0.314017 breast cancer prevention 0.340448 útero intacto 0.328063 Estados Unidos 0.337849 menor riesgo 0.381674 cancer prevention trial 0.330827 Women's Health Initiative 0.311811 principal factor 0.31767 Health Initiative 0.316067 from benign breast 0.320129 Breast density 0.313434 lobular breast 0.315708 English record linkage 0.310983 hormonas estrógeno 0.31642 health study 0.316005 benign breast 0.353338 Cancer Res Treat 0.315355 Cancer Risk Assessment 0.316082 Epidemiol Biomarkers Prev 0.309854	enfermedad proliferativa benigna 0.311069 Goss PE 0.314786 antecedentes familiares 0.49279 Breast Risk Calculator 0.318395 prospective cohort study 0.311422 breast cancer risk 0.370651 reducción promedio 0.315263 breast cancer 0.951386 cardiopatía coronaria 0.328283 riesgos instantáneos 0.314306 IBIS-I breast 0.313331 risk factor 0.343815 mujeres portadoras 0.329041 Cancer Surveillance System 0.312955 IBIS Breast Cancer 0.320333 heritable risk factor 0.311842 Risk Calculator Tool 0.311 Reino Unido 0.311996 Women’s Health Initiative 0.309787 Breast Cancer Referral 0.321555 parenchymal patterns as 0.309616 Otro estudio 0.316688 Breast Cancer Res 0.357313 mujeres jóvenes 0.346647	CLICK HERE
2069	National Cancer Institute	Html	es	Enfermedad de Paget de seno	Hoja informativa sobre la enfermedad de Paget de seno, un tipo poco común de cáncer que algunas veces se llama enfermedad de Paget del pezón o enfermedad de Paget de mama.	Lippincott Williams 0.227873 Tumor Characteristics 0.23784 Eisner MP 0.227823 cáncer invasor 0.852818 afecciones benignas 0.232299 Cody HS 0.226638 Female Breast 0.245015 posibles tumores 0.243494 long-term follow-up study 0.244429 Breast Cancer Research 0.268606 siglo xix sir 0.249073 breast-conserving therapy 0.228801 Lippman ME 0.226791 ganglios linfáticos centinela 0.294176 afección benigna 0.309089 SEER Program 0.276615 Kanitakis J 0.22651 estadio i 0.22947 Hasson D 0.226314 European Institute 0.226377 Keel GE 0.226988 PubMed Abstract 0.996634 Haffty BG 0.225876 clinical presentation 0.228015 Therapeutic options 0.226841	with radiotherapy 0.228051 Tucker SL 0.226414 Paget mamaria 0.499743 estadio iv 0.228625 End Results 0.22623 Griffith KA 0.226914 signo revelador 0.231703 proteína her2 0.228884 National Cancer Institute 0.247867 4th ed 0.228822 Sosnovskikh I 0.226721 Ries LAG 0.280943 edad promedio 0.227469 Breast Journal 0.241614 Osborne CK 0.226941 Sir James Paget 0.694935 Cancer Survival Among 0.251885 estadio iii 0.228362 Gatti G 0.22751 Retrieved April 0.227819 sentinel lymph 0.278815 European Academy 0.22756 extramammary paget 0.443981 Dimaio DJ 0.226799	CLICK HERE
3425	National Cancer Institute	Html	es	Estrés psicológico y el cáncer	Hoja informativa que describe los efectos del estrés en el cuerpo, los resultados de investigaciones sobre la relación entre el estrés y el cáncer e información sobre cómo superar el estrés.	Sood AK 0.430056 care standards from 0.338514 determinadas hormonas 0.324248 Antoni MH 0.367904 tumor biology 0.324968 metastatic switch 0.319814 Dahmoush L 0.320856 psychological distress 0.325611 DeGeest K 0.320069 Dy SM 0.323303 Discovery Medicine 0.320658 estrés resultante 0.422988 biobehavioral signaling pathways 0.342266 peor calidad 0.321062 immune system 0.320953 McDonald PG 0.320742 Host factors 0.321766 Supportive Oncology 0.337163 Cox BF 0.320273 Psychological stress 0.329279 elevated tumor 0.324862 print march 0.323271	biobehavioral perspective 0.328519 familiar cercano 0.324843 tejidos adiposos mamarios 0.340834 sympathetic nervous system 0.335164 Lutgendorf SK 0.581508 Martinez KA 0.323343 ratones portadores 0.329629 PubMed Abstract 0.950792 killer cell activity 0.340076 carcinoma patients 0.32286 meta-analytic study 0.320949 Social isolation 0.322911 Lei X 0.320438 Priceman SJ 0.320893 peores resultados 0.32033 Clinical Oncology 0.442906 primary breast 0.321519 Segerstrom SC 0.320085 Psychological Bulletin 0.326317 largo tiempo 0.321876 bloqueadores beta 0.426953	CLICK HERE
3674	National Cancer Institute	Html	en	About the Genomic Data Sharing (GDS) Policy	Find helpful information about the GDS Policy, including when the policy applies, example projects, and providing informed consent.	data 0.82822 subsequent research 0.542062 scale research projects 0.540547 case-by-case basis 0.523592 large-scale genomic data 0.566607 research 0.652936 research projects 0.576167 intramural research 0.556456 investigators 0.50707 future research 0.572423 genomic data 0.760118 Human Genome Research 0.527144 Sharing Repository list 0.531325 NIH repository 0.489091 research community 0.487992 non-human genomic data 0.67956 NIH-funded research projects 0.531999 broad sharing 0.547642 Intramural investigators 0.494528 Trans-NCI Data Sharing 0.55358 NIH Genomic Data 0.603222 NIH Deputy Director 0.524095 usual data 0.490789 data sharing 0.652134	NCI Scientific Program 0.534443 Rare Disease Act 0.50658 United States 0.504978 sample consent forms 0.527036 NCI-funded research 0.492053 small patient populations 0.504923 sample threshold 0.505219 alternative data sharing 0.62573 appropriate program directors 0.511229 appropriate NCI Program 0.550878 Phenotypic Data Subject 0.531651 intramural scientific director 0.629908 consent forms 0.555547 data sharing plan 0.62329 effective date 0.571535 smaller scale 0.517774 study data 0.489242 NCI Director 0.488407 NIH-designated data repositories 0.533934 data repositories 0.543247 Intramural projects 0.499743 gds policy 0.963933 time points 0.50548 Orphan Drug Act 0.506071	CLICK HERE
16831	National Cancer Institute	Html	en	Functional Genomics Research	NCI's Center for Cancer Genomics uses functional genomics to understand the impact of cancer genes and pathways, and how to target them effectively.	CTD² Network 0.438678 Wellcome Trust Sanger 0.539692 Cancer Target 0.513795 genome-wide techniques 0.446676 new ideas 0.464401 functional genomics 0.975263 genomic vulnerabilities 0.510701 functional genomics experiments 0.70252 clinical data 0.51781 abnormal proliferation 0.447258 functional cancer genomics 0.735243 functional genomic approaches 0.609867 new methods 0.442531 cutting-edge organoid 0.535662 Driver Discovery 0.445569 research community 0.441075 cancer care 0.532833 CTD2 Network 0.523145 structural genomics research 0.72197 large-scale genomic datasets 0.600198 cancer work 0.514288 cell models 0.464098 available drugs 0.442916 functional genomics research 0.95801 human tumors 0.440224	CRISPR-Cas9 technology 0.437797 particular genetic alterations 0.563867 gene perturbation experiments 0.559111 Cancer Research UK 0.609166 tumor organoid cultures 0.651279 cancer cells 0.526612 cancer cell lines 0.623629 publicly available bank 0.544919 Cancer Model Development 0.602943 genetic abnormalities 0.444289 new compounds 0.443968 Genome Characterization Pipeline 0.5568 structural genomics studies 0.680281 CCG researchers 0.496817 high-throughput drug screens 0.551758 clinical care 0.437267 publishing novel results 0.53823 patient biopsies 0.451112 petri dishes 0.439826 cancer genes 0.514196 cancer development 0.502413 next-generation cancer models 0.753989 Hubrecht Organoid Technology 0.640694 cancer biology 0.533186	CLICK HERE
16840	National Cancer Institute	Html	en	Companies Formed by PIs of the NCI Alliance for Nanotechnology in Cancer	The NCI Alliance for Nanotechnology in Cancer has continued to translate solutions from the bench to products. Find out the companies that have been formed by Alliance funded research.	clinical products 0.627038 Alliance members 0.614849 academic laboratories 0.654334 for-profit partners 0.714957 start-ups 0.300298 clinical communities 0.60175 venture capital funds 0.950483 investigators 0.301645 partnerships 0.289977 start-up companies 0.650807 patents 0.29414 large pharmaceutical companies 0.926075	translational research 0.68727 significant investment 0.618191 Alliance PIs 0.780886 efficient development 0.679103 IP 0.327964 Alliance model 0.651092 services 0.276826 start-up companies. 0.723832 technologies 0.28746 biotechnology firms 0.63767 form 0.28731 discoveries 0.300415	CLICK HERE